Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 23, 2021 at 04:35 am
Share
Mayinglong Pharmaceutical Group Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 860.956 million compared to CNY 335.170 million a year ago. Operating income was CNY 141.931 million compared to CNY 122.514 million a year ago. Net income was CNY 117.260 million compared to CNY 109.372 million a year ago. Basic earnings per share from continuing operations was CNY 0.27 compared to CNY 0.25 a year ago.
Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.
MAYINGLONG PHARMACEUTICAL GROUP CO., LTD. 